Precision BioSciences Expands HBV Trial, Bolstering cccDNA Elimination Strategy
Event summary
- Precision BioSciences received Clinical Trial Application (CTA) approval to expand the ELIMINATE-B trial for PBGENE-HBV in France and Romania.
- The expansion adds to existing trial sites in the UK, Moldova, New Zealand, Hong Kong, and the US.
- Patient screening in France and Romania is expected to begin in Q2 2026.
- The trial investigates PBGENE-HBV, a gene editing therapy targeting cccDNA, the root cause of chronic hepatitis B.
- PBGENE-HBV has received Fast Track designation from the FDA.
The big picture
Precision BioSciences’ expansion of the ELIMINATE-B trial represents a significant step in the race to develop a curative therapy for chronic hepatitis B, a disease affecting hundreds of millions globally. The company’s focus on eliminating cccDNA, rather than merely suppressing viral load, differentiates it from existing treatments and addresses a key unmet medical need. However, the success of this strategy remains contingent on demonstrating clinical efficacy and securing regulatory approval in a competitive landscape.
What we're watching
- Execution Risk
- The success of the trial expansion hinges on rapid site initiation and patient enrollment in France and Romania, which could be impacted by logistical challenges or investigator capacity.
- Regulatory Dynamics
- The FDA's continued acceptance of sustained loss of HBV DNA as an approvable endpoint will be crucial for PBGENE-HBV's potential market approval, and any shift in guidance could significantly alter the development pathway.
- Competitive Landscape
- The emergence of alternative therapies targeting hepatitis B, or advancements in existing treatments, could erode PBGENE-HBV’s competitive advantage and impact its commercial viability.
Related topics